|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-9-18
|
|
pubmed:abstractText |
The platinum compounds are the most active agents in the treatment of ovarian carcinoma. Phase II trials demonstrated the activity of paclitaxel in patients with disease clinically resistant to platinum-based front-line therapy, and phase III studies confirmed that a combination of paclitaxel plus a platinum was superior to cyclophosphamide plus a platinum. This study evaluated the activity of platinum in patients with bulky advanced disease treated with single-agent paclitaxel as front-line therapy on a Gynecologic Oncology Group protocol. Those patients who had persistent (stable) or progressive disease while receiving paclitaxel, or a recurrence of disease within 6 months of completing six cycles of paclitaxel therapy, received single-agent cisplatin.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/CA 12477,
http://linkedlifedata.com/resource/pubmed/grant/CA 12482,
http://linkedlifedata.com/resource/pubmed/grant/CA 12485,
http://linkedlifedata.com/resource/pubmed/grant/CA 12534,
http://linkedlifedata.com/resource/pubmed/grant/CA 13630,
http://linkedlifedata.com/resource/pubmed/grant/CA 13633,
http://linkedlifedata.com/resource/pubmed/grant/CA 15975,
http://linkedlifedata.com/resource/pubmed/grant/CA 15977,
http://linkedlifedata.com/resource/pubmed/grant/CA 16386,
http://linkedlifedata.com/resource/pubmed/grant/CA 16938,
http://linkedlifedata.com/resource/pubmed/grant/CA 19502,
http://linkedlifedata.com/resource/pubmed/grant/CA 21720,
http://linkedlifedata.com/resource/pubmed/grant/CA 21946,
http://linkedlifedata.com/resource/pubmed/grant/CA 23073,
http://linkedlifedata.com/resource/pubmed/grant/CA 23088,
http://linkedlifedata.com/resource/pubmed/grant/CA 23501,
http://linkedlifedata.com/resource/pubmed/grant/CA 23765,
http://linkedlifedata.com/resource/pubmed/grant/CA 27469,
http://linkedlifedata.com/resource/pubmed/grant/CA 28160,
http://linkedlifedata.com/resource/pubmed/grant/CA 34477,
http://linkedlifedata.com/resource/pubmed/grant/CA 35640,
http://linkedlifedata.com/resource/pubmed/grant/CA 37234,
http://linkedlifedata.com/resource/pubmed/grant/CA 37535,
http://linkedlifedata.com/resource/pubmed/grant/CA 37569,
http://linkedlifedata.com/resource/pubmed/grant/CA 40296,
http://linkedlifedata.com/resource/pubmed/grant/CA12484
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
90
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
581-6
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:13678728-Adult,
pubmed-meshheading:13678728-Aged,
pubmed-meshheading:13678728-Aged, 80 and over,
pubmed-meshheading:13678728-Antineoplastic Agents,
pubmed-meshheading:13678728-Cisplatin,
pubmed-meshheading:13678728-Disease Progression,
pubmed-meshheading:13678728-Disease-Free Survival,
pubmed-meshheading:13678728-Drug Administration Schedule,
pubmed-meshheading:13678728-Drug Resistance, Neoplasm,
pubmed-meshheading:13678728-Female,
pubmed-meshheading:13678728-Humans,
pubmed-meshheading:13678728-Middle Aged,
pubmed-meshheading:13678728-Neoplasm Recurrence, Local,
pubmed-meshheading:13678728-Ovarian Neoplasms,
pubmed-meshheading:13678728-Paclitaxel
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study.
|
|
pubmed:affiliation |
Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, MS 39216-4505, USA. jthigpen@medicine.umsmed.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study
|
